STERIS Croissance future
Future contrôle des critères 1/6
STERIS devrait augmenter ses bénéfices et son chiffre d'affaires de 9.5% et de 6.2% par an respectivement. Le BPA devrait croître de de 9.6% par an. Le rendement des capitaux propres devrait être 12.8% dans 3 ans.
Informations clés
9.5%
Taux de croissance des bénéfices
9.57%
Taux de croissance du BPA
| Medical Equipment croissance des bénéfices | 16.2% |
| Taux de croissance des recettes | 6.2% |
| Rendement futur des capitaux propres | 12.80% |
| Couverture par les analystes | Good |
| Dernière mise à jour | 05 Jun 2026 |
Mises à jour récentes de la croissance future
Recent updates
Seeking Alpha • Jun 09
Steris: Stable, Steady And Appealing
Summary Steris now trades at the low end of its $200–$250 range, with improved earnings and reduced leverage making valuations more attractive. Steris delivered nearly 9% revenue growth to $5.94B, with all segments contributing and organic growth at 7%, though Q4 growth slowed to 5%. Forward guidance targets $11.10–$11.30 EPS on 6–7% organic growth, with leverage at 1x and significant capacity for M&A or capital return. Steris' stable organic growth, reasonable 18–19x forward earnings multiple, and potential for larger M&A enhance its appeal amid sector headwinds. Read the full article on Seeking Alpha
Mise à jour du récit • Jun 04
STE: Share Repurchases And Earnings Outlook Will Support Future Upside
Analysts have trimmed their price target for STERIS to $256.86 from $279.29, citing updated assumptions for the discount rate, revenue growth, profit margin, and future P/E that collectively point to a lower fair value estimate. What's in the News STERIS announced a share repurchase program authorizing the company to buy back up to US$1,000 million of its ordinary shares.Mise à jour du récit • May 11
STE: Lower Discount Rate And Stable Assumptions Will Support Future Upside
Analysts have maintained their $279.29 price target for STERIS, supported by a slightly lower discount rate and minor adjustments to long-term revenue growth, profit margin, and future P/E assumptions. Valuation Changes Fair Value: Maintained at $279.29 per share, with no change in the updated analysis.Mise à jour du récit • Apr 26
STE: Share Repurchases And Stable Assumptions Will Support Future Upside
Analysts have reiterated a $279.29 price target for STERIS, citing largely unchanged assumptions on growth, margins, discount rate and future P/E as the basis for maintaining their current valuation framework. What's in the News From October 1, 2025 to December 31, 2025, STERIS repurchased 200,000 shares for US$51.96 million, representing 0.2% of its shares under an existing buyback program (Key Developments).Mise à jour du récit • Apr 11
STE: Completed Buyback And Stable Assumptions Will Support Future Upside
Analysts kept their fair value estimate for STERIS steady at about $279 per share, while slightly updating assumptions around discount rate, revenue growth, profit margin, and future P/E. This reflects fine tuning of their models rather than a shift in the core outlook.Mise à jour du récit • Mar 28
STE: Completed Buyback And Refined Assumptions Will Support Future Upside
Analysts have reduced their price target on STERIS by about $2 to reflect slightly updated assumptions for fair value, discount rate, revenue growth, profit margin, and forward P/E, while maintaining the overall thesis. What's in the News From October 1, 2025 to December 31, 2025, STERIS repurchased 200,000 shares for US$51.96 million, accounting for 0.2% of its shares.Article d’analyse • Mar 24
Is There Now An Opportunity In STERIS plc (NYSE:STE)?
STERIS plc ( NYSE:STE ) received a lot of attention from a substantial price movement on the NYSE over the last few...Mise à jour du récit • Mar 11
STE: Completed Share Repurchases And Stable Assumptions Will Support Future Upside
Analysts have kept their STERIS price target steady at $281.25, with only minor tweaks to assumptions around discount rate, revenue growth, profit margin, and future P/E that do not materially change their overall view of the stock's valuation. What's in the News From October 1, 2025 to December 31, 2025, STERIS repurchased 200,000 shares for US$51.96 million, representing 0.2% of shares.Mise à jour du récit • Feb 25
STE: Completed Share Repurchases And Steady Assumptions Will Support Future Upside
Analysts have slightly trimmed their fair value estimate for STERIS to about $281 from roughly $282, reflecting modest tweaks to assumptions on the discount rate, long term revenue growth, profit margin, and future P/E expectations. What's in the News From October 1, 2025 to December 31, 2025, STERIS repurchased 200,000 shares for US$51.96 million, representing 0.2% of its shares.Mise à jour du récit • Feb 10
STE: Modest Assumption Tweaks Will Support A More Upbeat Fair View
Analysts have slightly adjusted their price target for STERIS to US$281.63, reflecting updated assumptions for discount rate, revenue growth, profit margin, and future P/E. Together, these factors suggest a modest recalibration of expectations rather than a major shift in outlook.Mise à jour du récit • Jan 27
STE: Share Repurchases And Stable Outlook Will Support A Fair View
Analysts have kept their fair value estimate for STERIS steady at about $281.63 per share, while making only very small tweaks to assumptions such as the discount rate and future P/E, reflecting largely unchanged views on the company’s long term earnings power. What's in the News From July 1, 2025 to September 30, 2025, STERIS repurchased 400,000 shares, representing 0.41% of its shares, for $98.64 million under its existing buyback program (Key Developments).Mise à jour du récit • Jan 10
STE: Share Repurchases And Steady Guidance Will Support A Fair Outlook
Analysts have kept their fair value estimate for STERIS essentially unchanged at about US$281.63, citing only very small tweaks to assumptions such as the discount rate, revenue growth, profit margin and future P/E that do not materially affect their overall price target view. What's in the News STERIS repurchased 400,000 shares from July 1, 2025 to September 30, 2025, representing 0.41% of shares for US$98.64 million, as part of its ongoing buyback program.Article d’analyse • Jan 09
Here's Why STERIS (NYSE:STE) Has Caught The Eye Of Investors
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Article d’analyse • Dec 26
Earnings Tell The Story For STERIS plc (NYSE:STE)
With a price-to-earnings (or "P/E") ratio of 36.4x STERIS plc ( NYSE:STE ) may be sending very bearish signals at the...Mise à jour du récit • Dec 23
STE: Share Repurchases And Steady Guidance Will Support A Fair Future Outlook
Analysts have modestly raised their price target on STERIS to $281.63, reflecting slightly higher long term growth and profitability expectations, despite largely unchanged model assumptions. What's in the News STERIS completed a share repurchase tranche between July 1 and September 30, 2025, buying back 400,000 shares, or 0.41% of shares outstanding, for $98.64 million (Key Developments).Mise à jour du récit • Dec 09
STE: Modest Buybacks And Steady Guidance Will Support A Balanced Outlook
Analysts have modestly raised their price target on STERIS to approximately $282 per share from about $281.60, reflecting slightly lower perceived risk and a steady outlook for revenue growth, profit margins, and long term valuation multiples. What's in the News Completed a share repurchase program totaling 1,307,158 shares, or about 1.32% of shares outstanding, for $298.64 million under the buyback announced on May 3, 2023 (company filing).Mise à jour du récit • Nov 25
STE: Stable Outlook And Share Buybacks Will Shape Near-Term Performance
Analysts have raised their price target for STERIS from $278.38 to $281.63. This change reflects modest expectations for improved revenue growth, even though there have been minor adjustments to other key financial metrics.Mise à jour du récit • Nov 07
STE: Marginal Profit Margin Gains And Steady Outlook Will Influence Value
Analysts have raised their price target for STERIS from $272.38 to $278.38. They cite marginal improvements in projected profit margins, even though revenue growth expectations have been slightly reduced.Article d’analyse • Oct 27
Is STERIS (NYSE:STE) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Mise à jour du récit • Sep 05
Healthcare Demand And Facility Expansion Will Create Value
With STERIS’s discount rate and future P/E both virtually unchanged, analyst valuation perspectives remain steady, resulting in an unchanged consensus price target of $272.38. What's in the News STERIS completed $200 million in share repurchases, totaling 907,158 shares (0.92%) under its current buyback program; no additional shares were repurchased in the latest quarter.Article d’analyse • Aug 28
Calculating The Fair Value Of STERIS plc (NYSE:STE)
Key Insights STERIS' estimated fair value is US$227 based on 2 Stage Free Cash Flow to Equity With US$249 share price...Article d’analyse • Aug 07
STERIS (NYSE:STE) Is Paying Out A Larger Dividend Than Last Year
The board of STERIS plc ( NYSE:STE ) has announced that it will be increasing its dividend by 11% on the 26th of...Article d’analyse • Jul 06
Is There Now An Opportunity In STERIS plc (NYSE:STE)?
STERIS plc ( NYSE:STE ) saw a double-digit share price rise of over 10% in the past couple of months on the NYSE. The...Seeking Alpha • Mar 22
Steris: AST Recovery Is Ongoing; Upgrading To 'Strong Buy'
Summary Upgraded Steris to 'strong buy' with a fair value of $254 per share due to strong recovery in its Applied Sterilization Technologies (AST) business. AST segment showed 9.5% organic growth, with management confident in further recovery despite challenges from rising labor costs and raw material inflation. For FY25, Steris guides for 6% revenue growth and 3.1% adjusted EPS growth, with significant contributions expected from Healthcare Products and AST segments. Key risks include weak capital equipment sales due to economic conditions, but overall, Steris's differentiated AST portfolio supports a positive long-term outlook. Read the full article on Seeking AlphaSeeking Alpha • Nov 18
Steris Q2: Anticipating HSD Growth In AST, Upgrade To 'Buy'
Summary I am upgrading STERIS to a 'Buy' with a fair value of $240 per share due to the recent stock price pullback and solid growth prospects. STERIS reported 7.2% organic revenue growth and 5.4% adjusted EPS growth, with strong performance in the Applied Sterilization Technologies segment. Despite high interest rates, I anticipate a gradual recovery in the biotech industry, driving future double-digit revenue growth in STERIS' AST business. Key risks include potential legal liabilities from EtO emissions and weak near-term growth in healthcare capital equipment revenue. Read the full article on Seeking AlphaSeeking Alpha • Sep 16
Steris: Dental Divestiture, Surgical Instrumentation Acquisition, But Overvalued
Summary I reiterate a 'Hold' rating for Steris stock with a fair value of $220 per share, citing strong healthcare growth and overvaluation concerns. The divestiture of the dental business and acquisition of Surgical Instrumentation assets will allow Steris to focus on core healthcare and AST businesses. Steris reported 5.4% organic revenue growth and 7% adjusted EPS growth, driven by a 7.2% increase in AST business and strong healthcare performance. Despite strategic moves, cautious outlook on healthcare capital equipment spending due to high-interest rates supports maintaining a 'Hold' rating. Read the full article on Seeking Alpha
Nouveau récit • Aug 20
Robust Revenue Growth And Expanding Margins In The Medical Equipment Sector
Strong start to the fiscal year and gross margin improvements suggest underappreciated growth momentum and potential for expanding net margins.Seeking Alpha • Aug 13
Steris: Q2 Numbers Solidify Buy Thesis
Summary STE's Q1 FY'25 numbers were in line with expectations, with upsides in the healthcare and AST divisions. The company shows consistent free cash flow production and stable earnings on its capital base. I've revised our estimate on the intrinsic worth of the business to $270 per share, reiterating a buy. Read the full article on Seeking AlphaPrévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 3/31/2029 | 7,186 | 1,045 | N/A | N/A | 2 |
| 3/31/2028 | 6,773 | 984 | 978 | 1,427 | 8 |
| 3/31/2027 | 6,371 | 887 | 844 | 1,275 | 8 |
| 3/31/2026 | 5,936 | 782 | 972 | 1,341 | N/A |
| 12/31/2025 | 5,828 | 709 | 917 | 1,267 | N/A |
| 9/30/2025 | 5,702 | 689 | 961 | 1,301 | N/A |
| 6/30/2025 | 5,571 | 648 | 909 | 1,264 | N/A |
| 3/31/2025 | 5,460 | 610 | 778 | 1,148 | N/A |
| 12/31/2024 | 5,398 | 617 | 751 | 1,142 | N/A |
| 9/30/2024 | 5,326 | 591 | 680 | 1,101 | N/A |
| 6/30/2024 | 5,235 | 561 | 594 | 996 | N/A |
| 3/31/2024 | 5,139 | 551 | 613 | 973 | N/A |
| 12/31/2023 | 4,683 | 1,036 | 594 | 934 | N/A |
| 9/30/2023 | 4,601 | 1,012 | 535 | 849 | N/A |
| 6/30/2023 | 4,563 | 576 | 494 | 806 | N/A |
| 3/31/2023 | 4,536 | 557 | 395 | 757 | N/A |
| 12/31/2022 | 4,784 | -28 | 349 | 713 | N/A |
| 9/30/2022 | 4,777 | -8 | 399 | 752 | N/A |
| 6/30/2022 | 4,773 | 377 | 472 | 819 | N/A |
| 3/31/2022 | 4,223 | 285 | 397 | 685 | N/A |
| 12/31/2021 | 4,248 | 279 | 412 | 701 | N/A |
| 9/30/2021 | 3,848 | 250 | 400 | 662 | N/A |
| 6/30/2021 | 3,407 | 286 | 424 | 653 | N/A |
| 3/31/2021 | 3,108 | 397 | 450 | 690 | N/A |
| 12/31/2020 | 3,057 | 433 | 476 | 701 | N/A |
| 9/30/2020 | 3,022 | 424 | 400 | 627 | N/A |
| 6/30/2020 | 3,003 | 413 | 384 | 615 | N/A |
| 3/31/2020 | 3,031 | 408 | 376 | 591 | N/A |
| 12/31/2019 | 2,976 | 393 | N/A | 570 | N/A |
| 9/30/2019 | 2,898 | 336 | N/A | 573 | N/A |
| 6/30/2019 | 2,840 | 319 | N/A | 548 | N/A |
| 3/31/2019 | 2,782 | 304 | N/A | 540 | N/A |
| 12/31/2018 | 2,730 | 269 | N/A | 490 | N/A |
| 9/30/2018 | 2,696 | 316 | N/A | 467 | N/A |
| 6/30/2018 | 2,651 | 303 | N/A | 478 | N/A |
| 3/31/2018 | 2,620 | 291 | N/A | 458 | N/A |
| 12/31/2017 | 2,585 | 243 | N/A | 463 | N/A |
| 9/30/2017 | 2,570 | 144 | N/A | 453 | N/A |
| 6/30/2017 | 2,582 | 120 | N/A | 424 | N/A |
| 3/31/2017 | 2,613 | 110 | N/A | 424 | N/A |
| 12/31/2016 | 2,616 | 142 | N/A | 439 | N/A |
| 9/30/2016 | 2,588 | 167 | N/A | 364 | N/A |
| 6/30/2016 | 2,431 | 135 | N/A | 294 | N/A |
| 3/31/2016 | 2,233 | 111 | N/A | 255 | N/A |
| 12/31/2015 | 2,042 | 94 | N/A | 185 | N/A |
| 9/30/2015 | 1,897 | 113 | N/A | 221 | N/A |
| 6/30/2015 | 1,870 | 135 | N/A | 241 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de STE ( 9.5% par an) est supérieure au taux d'épargne ( 3.5% ).
Bénéfices vs marché: Les bénéfices de STE ( 9.5% par an) devraient croître plus lentement que le marché US ( 17.9% par an).
Croissance élevée des bénéfices: Les bénéfices de STE devraient augmenter, mais pas de manière significative.
Chiffre d'affaires vs marché: Le chiffre d'affaires de STE ( 6.2% par an) devrait croître plus lentement que le marché de US ( 12.5% par an).
Croissance élevée des revenus: Le chiffre d'affaires de STE ( 6.2% par an) devrait croître plus lentement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Le retour sur capitaux propres de STE devrait être faible dans 3 ans ( 12.8 %).
Découvrir les entreprises en croissance
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/06/11 16:16 |
| Cours de l'action en fin de journée | 2026/06/11 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2026/03/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
STERIS plc est couverte par 17 analystes. 8 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Michael Polark | Baird |
| Erin Wilson Wright | BofA Global Research |
| David Turkaly | Citizens JMP Securities, LLC |